A randomized clinical trial on improving osteopenia in postmenopausal women after two years of preventive treatment with alendronate; a dose of 35 mg per week is more effective or a dose of 70 mg?
Introduction: Osteoporosis is the most common metabolic bone disease worldwide. In this disease, the bone mass decreases and as it progresses, the risk of fracture increases. Osteopenia occurs in the early stages of bone loss. Studies on the effective dose for treatment of osteopenia have been contr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Diabetic Nephropathy Prevention
2020-01-01
|
| Series: | Journal of Preventive Epidemiology |
| Subjects: | |
| Online Access: | https://jprevepi.com/PDF/jpe-5-e16.pdf |